Johnson & Johnson and partner Legend Biotech are celebrating a big win in their efforts to expand the use of CAR-T therapy Carvykti for multiple myeloma, after showing a survival benefit in a phase 3 trial.The result – from the CARTITUDE-4 study in patients previously treated with between one and three prior lines of therapy – will give the companies a leg-up in their rivalry with Bristol-Myers Squibb in the market for BCMA-directed CAR-T therapies for the blood cancer.
